Engineers Gate Manager LP Puma Biotechnology, Inc. Transaction History

Engineers Gate Manager LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$2.23 - $4.49 $42,541 - $85,655	19,077 New	19,077 $82,000
Q4 2021 Feb 14, 2022	SELL	$2.85 - $6.58 $34,200 - $78,960	-12,000 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$6.63 - $9.39 $11,934 - $16,902	-1,800 Reduced 13.04%	12,000 $84,000
Q2 2021 Aug 16, 2021	SELL	$8.98 - $11.6 $58,370 - $75,400	-6,500 Reduced 32.02%	13,800 $127,000
Q1 2021 May 17, 2021	SELL	$9.38 - $13.63 $111,809 - $162,469	-11,920 Reduced 37.0%	20,300 $197,000
Q4 2020 Feb 16, 2021	BUY	$7.78 - $12.13 $138,701 - $216,253	17,828 Added 123.87%	32,220 $331,000
Q3 2020 Nov 16, 2020	SELL	$9.5 - $11.14 $168,416 - $197,489	-17,728 Reduced 55.19%	14,392 $145,000
Q2 2020 Aug 17, 2020	BUY	$7.01 - $13.24 $225,161 - $425,268	32,120 New	32,120 $335,000
Q1 2020 May 15, 2020	SELL	$6.28 - $14.57 $222,946 - $517,249	-35,501 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$6.5 - $10.73 $230,756 - $380,925	35,501 New	35,501 $311,000
Q3 2019 Nov 14, 2019	SELL	$8.75 - $12.85 $200,243 - $294,072	-22,885 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$12.3 - $35.76 $281,485 - $818,367	22,885 New	22,885 $291,000

101

29M

50.6K

16.3K

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $123M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

Stay updated on Engineers Gate Manager LP with notifications on news.